Table 1.

Pharmaceutical company-tested therapeutic strategies for Huntington’s disease (HD), using molecules that target huntingtin mRNA that are in clinical testing or close to the start of this phase.

Company	Technology/Strategy	Molecule	Clinical Phase
Ionis Pharmaceuticals/Roche	ASO/Non-allele-selective	RG6042	I/II—completed III—scheduled for completion in 2023
Wave Life Sciences/Takeda	ASO/Allele-selective	WVE-120101, WVE-120102	I/II—scheduled for completion in 2020
UniQure Biopharma	RNAi/Non-allele-selective	rAAV5-miHTT (AMT-130)	I/II—scheduled for completion in 2022
Voyager/Sanofi-Genzyme	RNAi/Non-allele-selective	AAV-shRNA (VY-HTT01)	-
Spark Therapeutics	RNAi/Non-allele-selective	AAV-shRNA	-